Clinical Trials Logo

Filter by:
NCT ID: NCT00238563 Withdrawn - Glaucoma Clinical Trials

Post-Operative Sub-Tenon Kenalog in Glaucoma Filtering Surgery

Start date: n/a
Phase: N/A
Study type: Interventional

Determine efficacy of sub tenon kenalog injections for post-operative management of trabeculectomy procedures.

NCT ID: NCT00243490 Withdrawn - Clinical trials for Glioblastoma Multiforme

Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors

Start date: n/a
Phase: Phase 2
Study type: Interventional

Primary Objective: - The primary objective is to evaluate the efficacy of photodynamic therapy in the treatment of malignant intracranial tumors. Secondary Objective: - The secondary objective is to evaluate the safety of photodynamic therapy in the treatment of malignant intracranial tumors.

NCT ID: NCT00246038 Withdrawn - Clinical trials for Abdominal Aortic Aneurysm

The Boston Scientific ENOVUS Trial

Start date: n/a
Phase: Phase 2
Study type: Interventional

A prospective, actively controlled, consecutively enrolling, non-randomized multi center clinical evaluation of the safety and efficacy of the Boston Scientific ENOVUS AAA Endograft when used in the treatment of patients with AAA (Treatment Group) as compared to patients treated with conventional open surgery (Control Group).

NCT ID: NCT00246675 Withdrawn - Clinical trials for Renal Impairment After Cardiac Surgery

Frusemide Infusion for the Prevention of Deterioration in Renal Function Post Cardiac Surgery.

Start date: n/a
Phase: N/A
Study type: Interventional

The purpose of the project is to test whether or not the commonly used medication frusemide, given after heart surgery, and aiming to increase urinary output can have an effect on kidney function.

NCT ID: NCT00250692 Withdrawn - Analgesic Affect Clinical Trials

A Study to Test the Pain-relieving Effect of Laughing Gas in Infants

Start date: n/a
Phase: Phase 3
Study type: Interventional

Our proposal is to study infants in the Neonatal Intensive Care Unit (NICU) who are undergoing a heel stick for blood sampling, a standard procedure in patient care. Currently, these infants do not get any pain relief for this procedure. Several recent clinical studies have shown the usefulness of nitrous oxide (laughing gas) for treating pain for minor procedures in children 0 to 18 years, but these effects have not been exclusively studied in the newborn and infant populations. Animal studies have questioned the anti-nociceptive (pain-blocking) effect of nitrous oxide in very young animals. It is unclear if this also applies to humans. The reason for this difference may be due to an immaturity of the neural pathways that modulate pain in the very young. The purpose of this study is to investigate whether or not nitrous oxide has an analgesic (pain-relieving) effect in infants undergoing minor procedures in the neonatal period (less than 3 months).

NCT ID: NCT00253526 Withdrawn - Clinical trials for Stage III Pancreatic Cancer

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Start date: n/a
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells an help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine hydrochloride together with bevacizumab after surgery may kill any remaining tumor cells. PURPOSE: This phase II trial is studying gemcitabine hydrochloride and bevacizumab to see how well they work compared to gemcitabine hydrochloride alone in treating patients who are undergoing surgery for pancreatic cancer.

NCT ID: NCT00253617 Withdrawn - Clinical trials for Unresectable Extrahepatic Bile Duct Cancer

Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery

Start date: n/a
Phase: Phase 3
Study type: Interventional

RATIONALE: Stent placement may help reduce symptoms caused by the tumor. Photodynamic therapy uses a drug, such as porfimer sodium, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. This may be an effective treatment for cholangiocarcinoma. It is not yet known whether stent placement and photodynamic therapy using porfimer sodium are more effective than stent placement alone in treating cholangiocarcinoma. PURPOSE: This randomized phase III trial is studying stent placement and photodynamic therapy using porfimer sodium to see how well they work compared to stent placement alone as palliative treatment in treating patients with stage III or stage IV cholangiocarcinoma that cannot be removed by surgery.

NCT ID: NCT00256035 Withdrawn - Atherosclerosis Clinical Trials

Interleukin-4 (IL-4) as a Marker of Atherosclerosis

Start date: n/a
Phase: N/A
Study type: Interventional

In recent years, medical research into the cause and progression of heart disease due to narrowing and blockage of blood vessels to the heart muscle has improved the understanding of ischemic heart disease. It is now accepted that both the development and later progression with sudden blockage of blood vessels are associated with inflammation, although it remains unknown exactly what triggers this inflammatory process. It is possible that new blood tests which measure markers of inflammation in the bloodstream may be useful to help identify patients at risk of heart damage and assess response to treatment. The study plans to assess a new blood test for a known marker of inflammation (IL-4) in patients with heart disease. The hypothesis of this study is that, the cytokine, IL-4, measured by a new assay, is abnormally elevated in the blood of patients with coronary artery disease. Also hypothesized is that the degree of abnormality of blood IL-4, is related to important clinical events in such patients, including severity of disease, acute complications, and treatment.

NCT ID: NCT00259571 Withdrawn - Ulcerative Colitis Clinical Trials

Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.

Start date: n/a
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate if retarded phosphatidylcholine is as effective as mesalazin in preventing an acute episode in ulcerative colitis. The hypothesis is, that ulcerative colitis is cuased by a defect in the barrier function of the colonic mucus. The background of the study is the finding that the phosphatidylcholine content of the colonic mucus is reduced in patients with ulcerative colitis, in both healthy and inflamed parts of the colon.

NCT ID: NCT00262353 Withdrawn - Clinical trials for Renal Failure, Chronic

Elimination of Protein-bound Uremic Retention Solutes by Prometheus Artificial Hepatic System Versus Conventional Dialysis

Start date: n/a
Phase: N/A
Study type: Interventional

Comparison of the efficacy of dialysis by conventional dialysis versus Prometheus artificial hepatic system